Development of indole/indazole-aminopyrimidines as inhibitors of c-Jun N-terminal kinase (JNK): optimization for JNK potency and physicochemical properties.

[1]  Johannes C. Hermann,et al.  Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead. , 2013, Bioorganic & medicinal chemistry letters.

[2]  P. Lograsso,et al.  Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[3]  M. Pellecchia,et al.  Synthesis and optimization of thiadiazole derivatives as a novel class of substrate competitive c-Jun N-terminal kinase inhibitors. , 2010, Bioorganic & medicinal chemistry.

[4]  P. Lograsso,et al.  Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors. , 2010, Journal of medicinal chemistry.

[5]  J. Mosley,et al.  1-Aryl-3,4-dihydroisoquinoline inhibitors of JNK3. , 2009, Bioorganic & medicinal chemistry letters.

[6]  Gavin Harper,et al.  Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. , 2008, Journal of medicinal chemistry.

[7]  P. Zarrinkar,et al.  High-throughput kinase profiling as a platform for drug discovery , 2008, Nature Reviews Drug Discovery.

[8]  Toshimasa Tanaka,et al.  Discovery, synthesis and biological evaluation of isoquinolones as novel and highly selective JNK inhibitors (2). , 2008, Bioorganic & medicinal chemistry.

[9]  Toshimasa Tanaka,et al.  Discovery, synthesis and biological evaluation of isoquinolones as novel and highly selective JNK inhibitors (1). , 2008, Bioorganic & medicinal chemistry.

[10]  T. Ceska,et al.  Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[11]  H. Sham,et al.  Hemodynamic effects of potent and selective JNK inhibitors in anesthetized rats: implication for targeting protein kinases in metabolic diseases. , 2007, Bioorganic & medicinal chemistry letters.

[12]  H. Sham,et al.  Aminopyridine carboxamides as c-Jun N-terminal kinase inhibitors: targeting the gatekeeper residue and beyond. , 2006, Bioorganic & medicinal chemistry letters.

[13]  Eric F. Johnson,et al.  Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors. , 2006, Journal of Medicinal Chemistry.

[14]  Chaohong Sun,et al.  Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. , 2006, Journal of medicinal chemistry.

[15]  S. Teague,et al.  Structure-driven HtL: design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity. , 2005, Bioorganic & medicinal chemistry letters.

[16]  K. Wellen,et al.  Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.

[17]  A. Manning,et al.  Targeting JNK for therapeutic benefit: from junk to gold? , 2003, Nature Reviews Drug Discovery.

[18]  H. K. Sluss,et al.  Selective interaction of JNK protein kinase isoforms with transcription factors. , 1996, The EMBO journal.

[19]  I. Tsigelny,et al.  JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. , 1994, Genes & development.

[20]  M. Karin,et al.  JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain , 1994, Cell.

[21]  J. Avruch,et al.  pp54 microtubule-associated protein 2 kinase. A novel serine/threonine protein kinase regulated by phosphorylation and stimulated by poly-L-lysine. , 1990, The Journal of biological chemistry.

[22]  C. A. Tolman,et al.  Steric effects of phosphorus ligands in organometallic chemistry and homogeneous catalysis , 1977 .

[23]  C. Miller,et al.  Developmental expression in the mouse nervous system of the p493F12 SAP kinase. , 1996, Brain research. Molecular brain research.